Neurosteroids alter glutamate-induced changes in neurite morphology of NG108-15 cells.
Activation of the NMDA receptor leads to increased intracellular Ca2+ levels ([Ca2+]i) which induces outgrowth of and morphologic changes in the neurites of the NG108-15 cell line. This effect can be blocked by antagonists for this glutamate receptor subtype (e.g. ifenprodil or AP5). We have previously shown that nanomolar concentrations of various neurosteroids modulate ifenprodil binding to the NMDA receptor. To investigate whether this interaction affects the functioning of the receptor, we studied the effect of 24 and 48 h of pregnenolone sulphate (PS) or pregnanolone sulphate (3alpha5betaS) on glutamate-stimulated NG108-15 cells. Unexpectedly, the neurosteroids themselves had an inhibitory effect on glutamate-induced changes in neurite patterns. This effect was comparable to that of ifenprodil or AP5. Moreover, the effect of combined treatment with 3alpha5betaS and ifenprodil on neurite morphology indicated a functional interaction between the substances. Interestingly, PS induced cell detachment over time, an effect that was further enhanced by ifenprodil. Cell detachment was also seen after 48 h of treatment with 3alpha5betaS; however, the effect was blocked by ifenprodil and weaker than that of PS. The interaction with the NR2B-selective antagonist ifenprodil indicates that this NMDA receptor subunit may be involved in neurosteroid-induced NG108-15 cell detachment.
Johansson
Tobias
T
Department of Pharmaceutical Biosciences, Division of Biological Research on Drug Dependence, Uppsala University, S-751 24 Uppsala, Sweden.
Elfverson
Martin
M
Birgner
Carolina
C
Frändberg
Per-Anders
PA
Nyberg
Fred
F
Le Grevès
Pierre
P
D015763:2-Amino-5-phosphonovalerate / Q000494:pharmacology; D002448:Cell Adhesion / Q000187:drug effects; D045744:Cell Line, Tumor; D018690:Excitatory Amino Acid Agonists / Q000378:metabolism / Q000494:pharmacology*; D005910:Glioma / Q000473:pathology; D018698:Glutamic Acid / Q000378:metabolism / Q000494:pharmacology*; D006801:Humans; D006822:Hybrid Cells / Q000473:pathology; D016501:Neurites / Q000187:drug effects* / Q000473:pathology; D009447:Neuroblastoma / Q000473:pathology; D010880:Piperidines / Q000494:pharmacology; D011284:Pregnenolone / Q000494:pharmacology; D016194:Receptors, N-Methyl-D-Aspartate / Q000037:antagonists & inhibitors / Q000378:metabolism*; D013256:Steroids / Q000494:pharmacology*
D018690:Excitatory Amino Acid Agonists; C121001:NR2B NMDA receptor; D010880:Piperidines; D016194:Receptors, N-Methyl-D-Aspartate; D013256:Steroids; C018370:pregnenolone sulfate; D018698:Glutamic Acid; D011284:Pregnenolone; D015763:2-Amino-5-phosphonovalerate; C010739:ifenprodil